Comparative evaluation of the immunogenicity of yeast-derived (recombinant) and plasma-derived hepatitis B vaccine in infants

Panda, Subrat K. ; Ramesh, Rajagopal ; Rao, Kanury V. S. ; Gupta, Asha ; Zuckerman, Arie J. ; Nayak, Nabeen C. (1991) Comparative evaluation of the immunogenicity of yeast-derived (recombinant) and plasma-derived hepatitis B vaccine in infants Journal of Medical Virology, 35 (4). pp. 297-302. ISSN 0146-6615

Full text not available from this repository.

Official URL: http://www3.interscience.wiley.com/journal/1122051...

Related URL: http://dx.doi.org/10.1002/jmv.1890350416

Abstract

The immunogenicity of plasma-derived (HB Vax, MSD) and recombinant hepatitis B virus (Engerix B, SKF) vaccines was evaluated in infants born to hepatitis B virus carrier mothers. The vaccination was carried out at 1 day, 1 month, and 6 months of age using 10 μ g of the vaccine given intramuscularly. A total of 83/88 (94.3%) and 74/79 (93.6%) of the infants receiving the plasma-derived vaccine and yeast-derived vaccine showed antibody to hepatitis B surface antigen (anti-HBs). None of the maternal factors studied apart from the HBeAg positivity corellated with vaccine failure. The yeast-derived vaccine gives marginally lower antibody titre than the plasma-derived vaccine. The group-specific anti-"a" antibody was less than 10% of the total anti-HBsAg titre. It was observed that the vaccine alone without prior administration of hepatitis B immunoglobulin is effective in perinatal infection.

Item Type:Article
Source:Copyright of this article belongs to John Wiley and Sons, Inc.
Keywords:HBV; HBV Carriers; HBV DNA; HBV Vaccine; Perinatal Transmission; Anti-"a" Titre
ID Code:24655
Deposited On:29 Nov 2010 10:11
Last Modified:10 Jun 2011 06:16

Repository Staff Only: item control page